Drugs / Cinobufacini
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02530398 | Jul 2015 → Apr 2018 | digestive system cancer, peritoneal neoplasm | Dongfang Hospital Beijing University of Chinese Medicine | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03843229 | Jan 2019 → Sep 2020 | liver cancer | The First Affiliated Hospital of Dalian Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT02860429 | Sep 2016 → Sep 2017 | digestive system neoplasm | Xiaonan Cui | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cinobufacini | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02860429 ↗ |
| Action | Inhibit | “it has the ability to contract blood vessels and inhibit the formation of tumor new vessels” NCT02530398 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins” NCT02530398 ↗ |
| Route | Other | “cinobufacini injection intraperitoneal treatment” NCT02530398 ↗ |